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Abstract 
Background: Decision-making in public health and health policy is complex and requires careful deliberation of 
many and sometimes conflicting normative and technical criteria. Several approaches and tools, such as multi-criteria 
decision analysis, health technology assessments and evidence-to-decision (EtD) frameworks, have been proposed 
to guide decision-makers in selecting the criteria most relevant and appropriate for a transparent decision-making 
process. This study forms part of the development of the WHO-INTEGRATE EtD framework, a framework rooted in 
global health norms and values as reflected in key documents of the World Health Organization and the United 
Nations system. The objective of this study was to provide a comprehensive overview of criteria used in or proposed 
for real-world decision-making processes, including guideline development, health technology assessment, resource 
allocation and others.
Methods: We conducted an overview of systematic reviews through a combination of systematic literature searches 
and extensive reference searches. Systematic reviews reporting criteria used for real-world health decision-making by 
governmental or non-governmental organization on a supranational, national, or programme level were included and 
their quality assessed through a bespoke critical appraisal tool. The criteria reported in the reviews were extracted, 
de-duplicated and sorted into first-level (i.e. criteria), second-level (i.e. sub-criteria) and third-level (i.e. decision aspects) 
categories. First-level categories were developed a priori using a normative approach; second- and third-level catego-
ries were developed inductively.
Results: We included 36 systematic reviews providing criteria, of which one met all and another eleven met at least 
five of the items of our critical appraisal tool. The criteria were subsumed into 8 criteria, 45 sub-criteria and 200 decision 
aspects. The first-level of the category system comprised the following seven substantive criteria: “Health-related bal-
ance of benefits and harms”; “Human and individual rights”; “Acceptability considerations”; “Societal considerations”; 
“Considerations of equity, equality and fairness”; “Cost and financial considerations”; and “Feasibility and health system 
considerations”. In addition, we identified an eight criterion “Evidence”.
Conclusion: This overview of systematic reviews provides a comprehensive overview of criteria used or suggested 
for real-world health decision-making. It also discusses key challenges in the selection of the most appropriate criteria 
and in seeking to implement a fair decision-making process.
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Background
Decision-making in public health and health policy is 
complex [1–3]. Processes that consider evidence and 
other considerations in a structured manner require 
a careful deliberation of many and often conflicting 
normative and technical criteria [4–10]. The choice of 
which of these criteria should be employed in the form 
of criteria has a profound impact on the outcome of 
the decision-making process. In many decision-mak-
ing processes directly addressing health, criteria have 
mostly been concerned with effectiveness and cost 
[10–13]. This is at odds with the complexity of real-
world decision making, were normative and feasibil-
ity considerations may act as key drivers of decisions 
(e.g. infringement of population health interventions 
on individual rights or interactions of interventions 
with other components of a health system) [14, 15]. 
The values and perceptions of different stakeholders 
with respect to normative and technical considerations 
often vary greatly both within and across societies. As 
there are various reasonable and defendable percep-
tions of which values and principles should guide the 
decision-making process and as there is no consensus 
on the right or best criteria, reasonable disagreement 
about the right decision or action is likely in pluralist 
societies [16].
Of course, many health-relevant decisions in public 
health policy and practice are made without adhering 
to structured decision-making processes based on pre-
defined sets of criteria, populating those with evidence 
and weighting the results. But in various areas of public 
health policy and practice, such structured processes 
are relied on in the evaluation or comparison of alter-
native interventions or modes of actions. This inter alia 
includes the allocation of resources [9], the setting of 
research priorities [8, 17], decision-making about pub-
lic health interventions [18], the assessment of health 
technologies for funding or reimbursement [19–21], 
or investment or disinvestment considerations [22]. 
Selecting the most appropriate and relevant criteria is 
a challenging but critical task in all of these structured 
decision-making processes.
The criteria used across different types of deci-
sions have been addressed in multiple reviews. Sev-
eral reviews have explored the criteria used when 
applying multi-criteria decision analysis (MCDA) [13, 
23–28], an”umbrella term to describe a collection of 
formal approaches which seek to take explicit account 
of multiple criteria in helping individuals or groups 
explore decisions that matter” [29]. Other reviews 
have explored the criteria employed in the context of 
health technology assessments (HTA), which intend 
to examine social, economic, organizational and ethi-
cal considerations in relation to health technologies in 
a comprehensive manner [30]; these covered both the 
criteria to inform decisions about health technologies 
by national or sub-national HTA institutions [19, 31–
33], and the criteria used for selecting the technologies 
or interventions a HTA is to be conducted on [8, 34]. In 
general, reviews have addressed criteria used for mak-
ing decisions on funding or implementing health inter-
ventions or technologies [9, 10, 22, 35–38], prioritizing 
research topics [39–41] or coverage decisions [7, 12, 42, 
43]. Reviews include criteria used on various levels of 
decision making (national, regional, or local), in differ-
ent contexts (e.g. high- vs. low-income countries), and 
proposed by various stakeholder groups (e.g. decision 
makers, beneficiaries/patients).
Against this background, we conducted this study as 
part of a larger research project to develop a new evi-
dence-to-decision (EtD) framework. The WHO-INTE-
GRATE EtD framework was developed to be firmly 
rooted in WHO norms and values and reflective of the 
changing global health landscape, and to encompass a 
comprehensive set of criteria suitable for decision mak-
ing on clinical practice, public health, and health system 
interventions [15]. Within the development process of 
the framework, we conducted this overview of systematic 
reviews de-novo with the objective to provide a compre-
hensive overview of criteria used or intended to be used 
in real-world health decisions. More details on the role 
of this review in the development process of the WHO-
INTEGRATE EtD framework is provided in our publica-
tion Rehfuess/Stratil et al. [15].
Methods
Our search strategy combined the terms “decision-mak-
ing”, “decision maker*”, “decision analysis”, “multi-criteria 
decision analysis”, “priority setting”, “resource allocation”, 
“policy-making” and “policy-maker*” and their syno-
nyms with the terms “criterion” and “criteria” as well as 
the terms “review*”, “literature search”, “mapping”, “meta 
analysis” and their synonyms. Searches were conducted 
in PubMed and focused on the occurrence of these 
search terms in title and abstract. As the term “criteria” 
is used in many adjacent fields (e.g. referring to treat-
ment or diagnostic decisions), we complemented these 
Keywords: Decision-making, Decisionmaking, Resource allocation, Priority-setting, HTA, Health technology 
assessment, Criteria, WHO, WHO-INTEGRATE
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systematic searches with hand searches of the references 
of all included studies.
Title and abstract screening was conducted using the 
software Rayyan [44]. Title and abstract screening as well 
as full-text screening was independently undertaken by 
two authors (JMS and AN), based on the inclusion and 
exclusion criteria shown in Table  1. We included stud-
ies which had conducted systematic searches of the lit-
erature and had comprehensively reported real-world 
criteria used in health decision-making. Studies focused 
on clinical decision-making (i.e. concerned with the deci-
sions of individual patients) as well as studies focussing 
on the concepts or measurements of individual criteria 
(e.g. cost-effectiveness) were excluded. Where discrepan-
cies could not be resolved by the two screening authors, a 
third author (ER) was consulted. Screening of the records 
identified through the updated literature searches was 
conducted by the author (JMS) and a research assistant 
(ST). The original literature searches were undertaken in 
September 2016 and updated in July 2018.
Information extracted from the included reviews were 
(i) study objective, (ii) type of health decision, (iii) the 
types of studies included, (iv) the strategy used to identify 
primary studies or documents, (v) information on how 
the criteria were compiled in the primary studies, (vi) the 
topic of the health decision in the primary studies (e.g. 
public health interventions, pharmaceuticals), (vii) the 
regional context of the primary studies (e.g. high- or low-
income countries), (viii) the decision-making level (e.g. 
national, regional, local) and, importantly, (ix) the criteria 
themselves.
We critically appraised included studies. As no 
adequate, validated critical appraisal tool was avail-
able, we adapted items of the CASP systematic review 
checklist [45] and AMSTAR 2 [46] to our research 
question (Additional file  1). Our critical appraisal 
tool focuses on (i) the formulation of a clear research 
question regarding the decision-making process to be 
explored, (ii) a comprehensive search strategy, (iii) the 
adequate selection of eligible studies, (iv) the compre-
hensive extraction of criteria, (v) the critical appraisal 
of primary studies, (vi) the adequate description of the 
identified criteria (vi) the consideration of potential 
conflicts of interest, and (vii) the use of pre-established 
methods. The critical appraisal was conducted by one 
author (JS) and cross-checked by a research assistant 
(ST).
Given the intended primary use of the WHO-INTE-
GRATE framework in the development of WHO guide-
lines, the analysis focuses on substantive criteria (i.e. 
“What are the considerations or criteria a decision 
should be based on?”; e.g. cost, health benefit, available 
resources) rather than procedural criteria (i.e. “How 
should the process through which a decision is made 
be organized?”; e.g. transparency, participation of key 
stakeholders, opportunity for revising decisions).
This information was extracted onto an Excel spread-
sheet by one author (JMS) and spot checked by a 
research assistant (ST). Wherever possible, criteria 
were extracted as stated in the primary studies. Where 
the reviews only reported synthesised criteria with-
out a direct link to the primary studies, we extracted 
these synthesised criteria (e.g. “disease burden” and 
“burden of illness” as reported in primary studies sum-
marized in a single “burden of disease” criterion in 
the included review). Categories, referring to the clas-
sification system developed or used in the reviews, 
were not extracted (e.g. “cost” and “cost-effectiveness” 
as reported in primary studies summarized under the 
criterion “financial considerations” in the included 
review). The criteria were then re-organised by one 
author (JMS) by combining (i) identical criteria (e.g. 
“burden of disease” and “burden of disease”) and (ii) 
criteria described through similar terms with the same 
meaning (e.g. “burden of disease”, “burden of illness” or 
“disease burden”).
The criteria were then synthesised in a mixed inductive 
and deductive approach:
Table 1 Inclusion and exclusion criteria for the overview of systematic reviews
Inclusion criteria Exclusion criteria
The publication is a review based on systematic searches of the literature
The publication is concerned with the criteria considered as part of a health 
decision between two or more options or the weighting of multiple 
options, made by a governmental or non-governmental organization on 
a supranational, national, or programme level
The health decision is made from a population perspective regarding the 
general population, patients, healthcare personnel, health decision-mak-
ers or other similar stakeholders in public health and healthcare
The publication reports on a comprehensive set of criteria identified 
through the literature searches (at least 3 criteria)
The publication is written in English, German, Spanish or Italian
The publication is not a literature review
The publication did not utilize a systematic search strategy
The publication is focused on selected criteria (e.g. cost-effectiveness) 
rather than sets of criteria guiding a decision
The publication relates to a health decision made outside of an organi-
zational context (e.g. General Practitioner’s office) and/or from an 
individual perspective (e.g. treatment choices for an individual patient 
in clinical practice)
The publication primarily addresses issues of how to measure, weight or 
calculate a criterion (e.g. cost-effectiveness, quality of life)
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For the deductive approach, we used an intermedi-
ate step in the development of the WHO-INTEGRATE 
framework [15], the seven so-called preliminary criteria 
“Health-related balance of benefits and harms”, “Human 
and individual rights”, “Acceptability considerations”, 
“Societal considerations”, “Considerations of equity, 
equality and fairness”, “Cost and financial considerations”, 
“Feasibility and health system considerations”, as well as 
“Evidence considerations” (Note that these categories 
were revised in the final WHO-INTEGRATE Frame-
work [15]). “Evidence considerations” was singled out to 
align with the role of evidence as a meta-criterion in the 
WHO-INTEGRATE Framework: rather than taking evi-
dence as one of several substantive decision-making cri-
teria into account, the framework argues for reflecting on 
the quality of evidence of each criterion and considering 
these aspects alongside. We used these—what we refer to 
as—criteria as level one of the category system. During 
the synthesis, we remained open-minded about revisions 
of the category system to be able to capture new consid-
erations relevant for decision making in an appropriate 
manner. For the inductive approach, we started from the 
criteria as reported in primary studies and reviews and 
grouped similar criteria into groups of—what we refer to 
as—sub-criteria (level two of the category system) and 
decision aspects (level three of the category system). Cri-
teria relating to decision-making principles, procedural 
criteria and research priority setting were extracted and 
categorized separately.
In cases where the exact meaning of a criterion was 
unclear, the primary publication was consulted wherever 
possible. Were uncertainty remained, these cases were 
discussed with a research assistant (ST) or with other 
members of the research team (ER; RB). After an initial 
sorting of criteria identified through the included reviews 
into the three-level category system, this was discussed 
and refined through discussions between JMS, ST, RB 
and ER; one author (JMS) subsequently conducted a sec-
ond round of sorting of the extracted criteria to ensure 
that all criteria, sub-criteria and decision aspects would 
be placed correctly within the category system.
Results
The literature search yielded 4448 unique records, of 
which 106 were assessed for eligibility based on their full 
text. A further 88 records were identified through hand 
searching (see Additional file 2 for PRISMA diagram).
We included 36 reviews in this overview of systematic 
reviews [4–8, 10–13, 19–23, 27, 28, 31–37, 39, 41–43, 
47–54]. All of these were published after 2006, with 15 
reviews published in 2018 or 2017 and only 5 reviews 
published before 2010. 16 reviews provided criteria used 
for or intended to guide various priority setting exercises 
[5, 6, 8, 11, 12, 31, 32, 34–36, 38, 41, 42, 49, 51, 55], with 
one review focused on research priority setting (in the 
field of child health and nutrition) [39]. Six reviews were 
framed in the context of multi-criteria decision analy-
sis [6, 13, 23, 27, 28, 48]. Three reviews explored criteria 
used to guide investment or disinvestment decisions [22, 
27, 37]. Two reviews assessed criteria to guide the selec-
tion of topics for HTA [8, 34], and eight reviews cap-
tured criteria used in HTA [8, 11, 19, 20, 31, 32, 48]. Four 
reviews focused specifically on the evaluation of or deci-
sions on vaccines [4, 21, 47, 55]. 19 reviews exclusively 
included studies or documents from high-income coun-
tries while five had an explicit focus on decision-making 
processes in low- and middle-income countries [10, 35, 
52, 55]. The number of criteria extracted from each pub-
lication ranged from 31 [4] to 360 [6].
The criteria, sub-criteria and decision aspects based on 
the -criteria extracted from the reviews are provided in 
Table  2. An additional category containing synthesized 
criteria extracted from the included reviews is provided 
in Additional file 3. The first level of the category system 
encompasses seven substantive criteria, i.e. “Health-
related balance of benefits and harms”, “Human and indi-
vidual rights”, “Acceptability considerations”, “Societal 
considerations”, “Considerations of equity, equality and 
fairness”, “Cost and financial considerations”, and “Fea-
sibility and health system considerations”. In addition to 
these substantive criteria, we also identified an eight cri-
terion “evidence” (Table 3). 
As criteria may be used in different decision-making 
processes and different decision-making contexts, not all 
criteria may apply. One important distinction, for exam-
ple, is whether the problem to be addressed (e.g. a spe-
cific disease) has already been decided on or not. If so, 
the decision is about selecting one out of several options 
to address the problem, and considerations regarding the 
priority of the problem itself (e.g. burden or severity of 
disease or disability) are no longer relevant.
As noted in the methods section, we sorted crite-
ria into a category system based on content. This way 
of organizing the criteria could be modified by adding 
additional dimensions. For example, one could also 
adopt a temporal perspective where criteria may relate 
to the point in time before an intervention is decided 
on or implemented the process of implementing the 
intervention or the short-term or longer-term outcome 
of the intervention. As an illustration, equity consid-
erations can be framed as relating to the starting point 
(e.g. priority of a given health issue due to high health 
inequity), as an criterion of relevance to the imple-
mentation process (e.g. distribution of adverse events 
across all those affected by the intervention) or as an 
outcome (e.g. reduced health inequity several years 
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Table 2 Overview of substantive criteria, sub-criteria, and decision aspects 
Criteria Sub-criteria Decision aspects
Health related balance of 
benefits and harms
General considerations surround-
ing benefit/effect
Benefits/effect/efficacy/effectiveness/impact [1, 2, 4–10, 12–15, 17–27, 29, 33–36]
Health related Benefits/effect/efficacy/effectiveness/impact [1, 2, 4, 8, 11–15, 21, 23, 
26, 31, 34, 35]
Uptake of intervention [15, 20, 34, 35]
Magnitude of benefit/effect/impact [2, 4, 11, 14, 18, 31, 33, 36]
Additional or indirect effects [2, 6, 33, 34]
Type and composition of effect/
benefit/impact [2]
Impact on mortality, survival, longevity and life expectancy [1, 2, 4, 11, 16, 19, 21, 
24–26, 28, 34–36]
Last chance therapies [23, 24]
Impact on morbidity and disability [1, 2, 16, 35]
Potential changes in health consequences [24, 25]
Impact on (health-related) quality of life [2, 8, 11, 12, 14, 19, 20, 22, 25, 26, 28, 29, 31, 33, 
35, 36]
Impact on patient-reported outcomes [2, 12, 16, 21, 26]
Valuation of health outcomes by patients and desirability of the effects [2]
Preventive benefits/effects or preventive approaches [1, 2, 4, 5, 16, 21, 25, 26, 31]
Character of benefit or effect Onset of effect and time until benefit [2, 11, 13]
Duration, sustainability and lasting effect [2, 11, 13, 15, 27, 31]
Individual and population level 
of benefit
Clinical benefits/effectiveness/impact [2, 3, 5, 11, 14, 17–22, 24, 25, 28, 31–33, 36]
Individual level benefit, effectiveness or impact [1, 2, 4, 18, 21, 22, 25, 26, 36]
Marginal benefits (for every patient) [20, 26]
Population level benefit, effectiveness or impact [1–5, 9, 12, 16, 18, 19, 24–27, 31, 34, 
35]
Threshold effectiveness on populations (herd immunity) [15, 34]
Balance of benefits and harms Balance of (health) benefits and harms [5, 14, 18, 19, 23, 24, 34]
General considerations surround-
ing harm/risk
General safety, risk and tolerability of intervention [2, 4, 5, 7–9, 11–17, 19–26, 29, 31, 
33–36]
Magnitude and likelihood of adverse events [26, 33–35]
Valuation of health outcomes by patients and desirability of the effects regarding 
harms [34]
Short and long term risk and safety profile [26]
Over diagnosis and over treatment [16, 26]
Stigmatization [2, 26]
Risk of failure of intervention [15, 34, 35]
Burden of treatment [2, 26, 33]
Risk of inappropriate use [8, 16, 25, 26]
Impact on disease patterns and reduced long-term effectiveness [15, 34]
Other or additional adverse events [2]
Health-related need and priority Health-related needs: in general [1, 2, 11, 14, 22, 23, 24]
Burden and impact of disease: in general [1, 2, 4, 7–10, 13–16, 21, 23–26, 33, 34, 36]
Magnitude of the problem [4, 10, 25, 34]
Burden of disease measured through epidemiological indicators [1, 2, 4, 5, 8, 11, 
13–15, 21, 23–26, 28, 33–36]
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Table 2 (continued)
Criteria Sub-criteria Decision aspects
Size of affected population and number of potential beneficiaries [1, 2, 4, 5, 8, 10, 11, 
13–17, 20–26, 28, 31–34, 36]
Maximum potential for disease burden reduction [10]
Severity of disease/condition: in general [1, 2, 4, 5, 9–12, 14, 16–19, 21–26, 28, 29, 31, 
33–36]
Severity of disease/condition: long term outcomes [34, 35]
Severity of disease/condition:
life threatening disease/condition and prognosis without treatment [1, 5, 11, 16, 21, 
28, 29, 34]
Severity of disease/condition:
late stage or end-of life status of disease/condition [5, 21, 24, 25, 28, 29, 36]
Outbreaks and epidemic potential [15, 34]
Urgency and emergencies [1, 2, 13, 25]
Human and
individual
rights
Human rights considerations [2, 11, 12, 20, 36]
Autonomy and informed consent [2, 11, 35]
Privacy and confidentiality [26, 35]
Intrusiveness of intervention [22]
Acceptability considera-
tions
Perceived priority of the problem Public perception of disease burden, disease risk or severity [15, 34, 35]
Acceptability Acceptability in general [2, 4, 6, 14, 15, 24, 26, 27, 34–36]
Acceptability of cost and financial outcomes [2, 14, 25, 26, 34]
Acceptability by beneficiaries Acceptability by beneficiaries: in general [2, 6, 8, 11, 15, 16, 26, 35]
Comfort, convenience and user experience [2, 11, 12, 14, 15, 20, 24–26, 31, 33, 35]
Acceptability by those providing 
intervention
Acceptability by those providing intervention [15, 16, 34, 35]
Social and cultural acceptability Social and cultural acceptability [2, 4, 8, 9, 11, 15, 18, 21, 22, 25, 26, 31–34, 36]
Ethical/moral acceptability [2, 6, 11, 12, 15, 18, 22, 25, 26, 32–34, 36]
Stakeholder demand, interests 
and pressures
Advocacy and stakeholder (in general) interests and pressures [1, 2, 6, 14, 15, 21, 25, 
33, 36]
Demands, interest and pressures of the public [1, 2, 8, 14, 24–26, 36]
Demands, interest and pressures by industry [2]
Pressures, demand and interest of beneficiaries and patient representatives [2, 17, 20, 
22, 25, 32, 33]
Pressures, demand and interest of those providing intervention [2, 17, 20, 25, 26, 32, 
33]
Media attention and coverage [1, 32]
Societal considerations Societal needs and priority Social burden of disease (individual/population) [8, 18, 21, 29, 34, 35]
Social needs [24]
Economic burden of disease on society (in general) [32]
Social and societal impact Social impact or benefits [2, 3, 5, 6, 14, 21, 23–26, 31, 33, 35]
Impact on non-health outcomes (in general) [15, 18, 26, 34]
Impact on poverty [1, 2, 4, 14, 25, 26, 36]
Relevance to social development of the country [10]
Value of hope [11]
Raise profile of condition [14]
Impact on economy Impact on economy [2, 25, 26]
Impact on productivity and population in productive age [2, 12, 16, 25]
Relevance to economic development of the country
Innovativeness (potential to encourage innovation) [2, 9, 10, 14, 21, 23–25, 31]
Environmental impact Environmental and/or ecological impact of intervention (in general) [14, 16, 21, 29–31, 
33]
Impact on future generations Impact on future generations [19]
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Table 2 (continued)
Criteria Sub-criteria Decision aspects
Considerations of equity, 
equality and fairness
Equity and equality Equity/equality considerations:
in general [1–4, 9–11, 14, 15, 18, 19, 22–24, 26, 27, 29, 33–36]
Fairness considerations:
in general [2, 3, 6, 11, 16, 26, 36]
Impact on (health) (in-)equity/(in-)equality [2, 6, 10, 14, 26, 31, 34, 35]
Distribution of benefits and harms [10, 26]
Accessibility Accessibility in general [2–4, 6, 9, 14–17, 19, 21, 24, 29, 31, 33–35]
Equity in accessibility [1, 2, 4, 6, 7, 11, 25, 26, 35]
Physical and spacial accessibility [2, 4, 6, 16, 26]
Timeliness of access (time spent waiting for treatment) [2, 3, 22, 36]
Informational accessibility [11]
Financial accessibility of intervention/Affordability [4, 9, 10, 12, 14, 19, 25, 26, 34–36]
Affordability: risk of catastrophic health expenditure [11, 16, 25]
Affordability: cost and Financial impact on beneficiaries [11, 13, 14, 16, 22, 25, 26, 31, 
34, 35]
Availability Availability/lack of suitable alternatives [1, 2, 5, 11, 12, 14, 17, 19–25, 28, 32, 34–36]
Limitations of alternative interventions [2, 11, 14, 15, 25, 26, 34, 35]
Rare diseases/orphan disease [12, 14, 16, 21, 24, 28]
Unmet needs [11, 12, 16, 21, 24, 29]
Responsibility Ability to reduce own health risk and conditions arising from patient behavior [4, 5, 11, 
16, 24, 25]
Non-discrimination Non-discrimination [11, 23, 24]
Consideration regarding specific 
populations
Consideration of high-risk populations [2, 11, 14, 26]
Consideration of vulnerable populations [1, 2, 4, 11, 21, 25, 26]
Consideration of Socio-economic status [4, 16, 25, 26, 36]
Consideration of sex, gender, and/or sexual orientation [2, 6, 16, 25, 26, 34]
Consideration of race/ethnicity [25, 36]
Consideration of care giver responsibilities [29]
Consideration of age-groups [1, 2, 4, 11, 14, 16, 26, 28]
Consideration of place of living [11, 16, 25]
Consideration of identity and ideology [25]
Other group related considerations [11]
Cost and financial consid-
erations
Financial burden of disease Financial burden of disease or current intervention on health system [2, 15, 16, 25, 32, 
34, 35]
Cost and budget impact of 
intervention
Cost/budget impact:
in general [1, 2, 4–6, 8, 9, 11–19, 21–23, 25–31, 33–36]
Cost per unit/usage [1, 2, 5, 11, 15, 17, 20, 23–26, 33, 34, 36]
Cost over time [20, 21, 25, 32, 34]
Long term cost/budget impact [25]
Overall cost/budget impact [1, 2, 11, 22, 26, 36]
Direct cost [11, 25, 32, 34, 35]
Indirect/additional/hidden cost [11, 34–36]
Marginal cost [11, 25]
Opportunity cost [2, 11, 21, 31]
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Table 2 (continued)
Criteria Sub-criteria Decision aspects
Impact on other spending/investments [2, 6, 14, 25]
Investment/start-up cost [2, 22, 30]
Operating cost [2, 30]
Lifecycle cost of intervention/technology [30]
Economic/financial benefits and cost-minimization potential [1, 3, 8, 11, 13, 22, 25, 27, 
28, 34–36]
Cost to/budget impact on government or society [1, 2, 5, 18, 25, 26, 29, 33, 36]
Relation of cost and benefits Relation of cost and benefits [1–7, 9–16, 18–26, 28, 31–36]
Financial context Appropriateness [2, 14]
Financial feasibility Affordability to health system
Availability or lack of funds/funding [1–4, 6, 10–12, 14, 15, 21–25, 31, 34, 36]
Financial sustainability Financial sustainability of intervention and consistency of funding [4, 11, 15, 31, 34]
Feasibility and health sys-
tem considerations
Health-system related needs and 
priority
Burden of disease on health system [2, 25, 26, 31, 33, 34]
Needs of the health-system
Feasibility and capacity to imple-
ment
General feasibility considerations [2–4, 7, 9, 10, 14–16, 22–27, 31, 33, 34, 36]
Technical feasibility considerations [6, 26, 33]
Practical feasibility considerations [4, 6, 26]
Capacity to implement [1, 2, 6, 14, 21, 25, 29]
Considerations of management 
and organization of health 
system
Availability of, capacity of and need for management and organizational structure [1, 
2, 16, 22, 26, 34]
Impact on management and organizational structure [2, 8, 11, 25]
Logistical considerations [2, 15, 34]
Availability of, capacity of and need for monitoring, surveillance and information 
system [34, 35]
Resource considerations Availability of, capacity of and need for resources (in general) [1, 2, 10, 14, 30, 36]
Impact on resources (in general) [2, 22–24]
Efficiency of resource use [18, 24, 31]
Considerations of human 
resources and their skills
Availability of, capacity of and need for human resources [2, 10, 13, 14, 18, 22, 26, 30]
Availability of, capacity of and need for skill levels/knowledge of human resources [2, 
3, 14, 16, 22, 25, 30, 35]
Impact on human resources and skill levels [2, 14, 18, 25, 31]
Considerations of Non-financial 
physical resources (equipment, 
infrastructure)
Capacity of, availability of need for of physical resources and infrastructure [16, 18, 22, 
25, 26, 34–36]
Impact on non-financial physical resources and infrastructure [18]
Interaction with and impact on 
health system
Impact on performance of health system
and impact on other services [1, 2, 4, 6, 8, 10, 11, 14, 16, 18, 20, 22, 26, 31, 33–35]
Interaction and compatibility with other health system components [1–3, 6, 14, 22, 25, 
33–35]
Ease of use, application and burden of intervention [13, 15, 22, 26, 35]
Appropriateness within health 
system
Appropriateness (in general) [2, 3, 11, 21, 25, 26, 31, 36]
Appropriateness of intervention for specific context [2, 16, 30]
Legislative and regulatory consid-
erations
Adherence to legal requirements, constrains and implications [2, 8, 10, 15, 16, 18, 25, 
26, 31–35]
Adherence to other directives, standards and requirements [2, 6, 14, 22, 30, 34]
Political considerations Political acceptability, interests and pressures [1–4, 6, 10, 11, 14, 18, 21, 25, 26, 33–36]
Donor and global interests and pressures [2, 3]
Political impact [2, 25, 33, 35]
Alignment with priorities [1–4, 6, 13–15, 21, 23, 24, 26, 29, 30, 34, 35]
Mission, mandate and goals of health system [2, 13, 14, 21, 25]
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after introducing the intervention). Further additional 
dimensions could be a focus on individuals, popula-
tions or systems (e.g. clinical health benefits for the 
individual, reduction of the disease burden of a popula-
tion, or impact on the performance of a health system 
following an intervention). In the organization of the 
criteria, we kept such additional organizational dimen-
sions in mind.
The most frequently reported criteria were health-
related impact of interventions, cost, cost-effectiveness 
and political interests or priorities; these were covered 
in all of the included reviews. Rarely used criteria were 
concerned with the environmental or societal impacts 
of interventions, and (non-financial) resource availabil-
ity/needs. The granularity (level of detail with respect to 
sub-criteria/aspects) varied widely depending on the cri-
terion: the criteria related to cost or financial considera-
tions included general (e.g. “resource use” or “cost”) as 
well as very specific usages (e.g. distinct ways to quan-
tify cost-effectiveness). In contrast, criteria related to the 
societal or environmental impacts of interventions, as 
well as considerations regarding equity or equality were 
usually reported in very generic terms.
Evidence in general or evidence regarding specific cri-
teria was mentioned in most included reviews, most 
often using generic terms, such as “evidence”. In some 
cases, the criterion evidence referred to specific meas-
ures, primarily “evidence of effectiveness/efficacy” and 
sometimes “evidence on cost”. In other reviews, this 
included criteria regarding the relevance of the available 
evidence for a given context (e.g. “relevance of evidence” 
or “generalizability of evidence”) and criteria regarding 
the quality of evidence (e.g. “certainty of evidence”, “cred-
ibility of evidence” or “validity of evidence”) (see Table 3 
and Additional file 4).
We also identified several considerations of specific 
relevance to research priority setting, covering con-
siderations regarding the answerability of the research 
question, research ethics or avoidance of duplication of 
research. As those were not the primary focus of this 
Table 2 (continued)
Criteria Sub-criteria Decision aspects
Strategic considerations Strategic planning and considerations [1, 2, 13, 19, 25, 31]
Existing cooperation [2, 10, 14, 22]
Decisions and practice of other institutions or stakeholders [2, 11, 17, 24, 29, 34]
Alignment with recommendations, guidelines and standards [1–3, 7, 11, 14, 16, 21, 24, 
26, 29, 34]
Historical context and past decisions [1–3, 11, 13, 14, 17, 19–22, 25]
Availability of incentives [1, 2]
Impact on future decisions [6, 14]
Keeping promises and commitments [2, 13]
Characteristic of intervention (technical) Complexity of intervention [2, 4, 6, 16, 21]
Scalability of intervention [9, 27]
Ability to evaluate intervention [2, 33–35]
Reversibility of intervention [2]
Flexibility of implementation [2]
Uniqueness [21]
Frequency of use and expected level of usage/activity [1, 2, 6, 8, 14, 25, 26, 32]
Dependence on maintenance [26, 30]
Sustainability of intervention utilization
(e.g. Supply of parts, vaccines) [2, 14, 15, 27, 29, 34]
Position of intervention in care pathway [5, 12, 20, 24]
Additional uses of intervention [5, 21, 23–25]
1 Youngkong et al. 2009 [10], 2 Guindo et al. 2012 [6]; 3 Waithaka et al. 2018 [36]; 4 Wiseman et al. 2016 [35], 5 Fischer 2012 [43], 6 Wahlster et al. 2015 [13], 7 Ricciardi 
et al. 2015 [47], 8 Specchia et al. 2015 [34], 9 Hayati 2018 [42], 10 McGregor et al. 2014 [41], 11 MacLeod et al. 2016 [7], 12 Angelis et al. 2018 [48], 13 Barasa et al. 
2015 [57], 14 Cromwell et al. 2015 [5], 15 Burchett et al. 2012 [4], 16 Varela-Lema et al. 2016 [38], 17 Vuorenkoski et al. 2008 [12], 18 Cowles et al. 2017 [50], 19 Golan 
et al. 2011 [33], 20 Erntoft et al. 2011 [51], 21 Friedmann et al. 2018 [28], 22 Ølholm et al. 2015 [37], 23 Stafinski et al. 2011a [19], 24 Stafinski et al. 2011b [20], 25 
Mobinizadeh et al. 2016 [32], 26 Marsh et al. 2014 [27], 27 Rudan et al. 2017 [39], 28 Ghijben et al. 2018 [31], 29 Drake et al. 2017 [23], 30 Diaconu et al. 2017 [52], 31 
Polisena et al. 2013 [22], 32 Noorani et al. 2007 [8], 33 Johnson et al. 2009 [53], 34 González-Lorenzo et al. 2015 [54], 35 Piso et al. 2009 [21], 36 Niessen et al. 2012 [11]
The publication by Niessen et al. (Ref. 36) is highlighted in italic, as it is the only study meeting all criteria of our critical appraisal tool
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publication, they are not further discussed here but listed 
in Additional file 4.
Furthermore, the included publications reported sev-
eral decision-making principles (i.e. guiding concepts 
from which different criteria derive). The distinction 
between decision-making principles and substantive cri-
teria is not always clear cut. For example, human rights 
can be regarded as an underlying principle from which 
other criteria derive (as used in the human rights-based 
framework by Bustreo et al. [56]), as well as a specific cri-
terion (assessing whether the intervention is in accord-
ance with human rights). From the publications included 
in our overview of systematic reviews, the following 
criteria were extracted: Beneficence, non-maleficence, 
fairness, diversity, fair innings, proportional shortfall, 
concern for the worse off, justice, formal justice, social 
justice, distributive justice, principles of human rights, 
principle of human dignity; marginal utility principle, 
principle of need and solidarity, collectivism, cohesion, 
mutuality, rule of rescue and Rawls’ difference principle 
(see Additional file 4).
Table 2 provides an overview of the criteria, sub-crite-
ria and decision aspects for the seven substantive criteria. 
Criteria relating to evidence are reported in Table 3.
The results of the critical appraisal are provided in 
Additional file  5. Only one publication, Niessen et  al. 
[11], met all eight items; 11 out of 36 publications met 
five or more items. Most publications did not conduct a 
critical appraisal of included studies, did not report inde-
pendent extraction of criteria by two reviewers, and did 
not state explicitly, that the review had been undertaken 
based on a protocol or otherwise pre-established meth-
ods (Additional file 5).
Discussion
Summary of findings
Drawing on 36 included reviews, we identified a set of 
200 unique decision aspects. These were sorted into 7 
substantive criteria und 45 sub-criteria as well as a sepa-
rate criterion on evidence. The substantive criteria cover 
health-related balance of benefits and harms; human 
and individual rights; acceptability considerations; soci-
etal considerations; considerations of equity, equality 
and fairness; cost and financial considerations; and fea-
sibility and health system considerations. We found that 
some criteria, sub-criteria and decision aspects are well 
developed in the literature, such as those referring to the 
health implications of an interventions or to the costs 
of an intervention. In contrast, several others lacked a 
clear conceptualisation, notably those relating to societal 
implications or equity and equality considerations.
The wide range of decision aspects were used to refine 
the criteria and sub-criteria in the WHO-INTEGRATE 
EtD framework, as well as to inform the development of 
definitions and guiding questions provided as part of the 
framework.
In addition to their use in the WHO-INTEGRATE 
framework, we postulate that the list of criteria, sub-
criteria and decision aspects can be helpful to decision-
makers in their own right: To the best of our knowledge, 
this is the most comprehensive and up-to-date list of 
real-world criteria available for health decision-making. 
It could therefore provide a valuable tool for informing 
decision-makers wishing to select those criteria relevant 
for a given type of decision and decision-making context. 
This comprehensive list is likely to be most relevant to 
decisions in public health or healthcare. Due to the focus 
of the present study, the applicability for research priority 
setting or the evaluation of diagnostic or testing devices 
is likely to be more limited, as we may not have covered 
all relevant publications.
Most of the reviews included in our overview of sys-
tematic reviews did not meet all or even a majority of 
the items of our critical appraisal tool. This finding does, 
however, need to be interpreted in view of the follow-
ing considerations. First, a validated critical appraisal 
tool appropriate for the topic does not exist—neither 
at the level of systematic reviews nor at the level of pri-
mary studies. Only three of the included reviews under-
took some form of critical appraisal: Whaitaka et al. [36] 
and Burchett et al. [4] used an adapted CASP Qualitative 
Checklist and Niessen et  al. [11] used custom quality-
of-research assessment scales. Second, the low score of 
Table 3 Overview of evidence considerations
Criteria Decision aspects
Evidence Con-
siderations
evidence in general [1, 2, 11–13, 15, 17, 21, 23, 31, 33, 
36]
strength of evidence in general [2, 11, 12, 21, 25, 36]
Certainty of evidence (in general) [2, 5, 6, 11, 16, 21–24, 
26, 28, 33, 36]
Quality of evidence [2, 4–6, 11, 14–22, 25, 26, 28, 29, 33, 
34, 36]
Completeness of evidence [2, 6, 12, 14, 25, 26]
Validity of evidence [2, 6, 25, 26, 29, 36]
Credibility of evidence [29, 34, 36]
directness of evidence [2, 11, 28]
Consistency of evidence [2, 6, 14, 25, 26, 29, 33]
Precision of evidence effect [2]
Relevance of evidence [2, 6, 11, 25–29]
Applicability and generalizability of evidence [2, 11, 22]
Type and quality of evidence sources [2, 11, 17, 21, 34, 
35]
Experience based evidence [26, 34, 35]
Evidence requirements [2, 5, 25]
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some of the included reviews is likely due to poor report-
ing rather than poor conduct (e.g. regarding pre-estab-
lished methods, or data extraction in duplicate).Third, the 
value and relevance of criteria for a given decision-mak-
ing process does not necessarily depend on the quality of 
the review they were derived from. For example, even if 
the criterion “environmental impact” was merely men-
tioned in a single systematic review of low quality, this 
would not invalidate its relevance for a decision-making 
process focused on interventions with pronounced envi-
ronmental (adverse) effect (e.g. large-scale usage of DDT 
in malaria prevention).
Contextualization of findings
With our overview of systematic reviews, we build on 
several previously published reviews, notably, the review 
by Guindo and colleagues, which represented the most 
extensive general overview of criteria until now [6]. 
Rather than focusing on specific decision-making pro-
cesses (e.g. priority setting in low- and middle-income 
countries), we sought to cover the full range and het-
erogeneity of criteria and their use across various health 
fields.
We followed an approach focusing on descriptive 
(“what criteria are used?”), rather than prescriptive 
(“what criteria should be used?”) approach. Several over-
views of more prescriptive frameworks have been pub-
lished in the field of public-health ethics in recent years 
[58–60]. A similar undertaking—providing decision-
makers with a basis to select appropriate criteria—was 
conducted by Vermeulen and Krabbe, who provided an 
overview of the most widely recognized arguments and 
principles used in decision-making [18]. Their more pre-
scriptive publication, which explores decision arguments 
and principles, and our more descriptive publication 
complement each other.
In contrast to some of the other reviews of criteria for 
decision making [6, 10], we abstained from quantifying 
how often criteria were cited for several reasons: First, 
the focus of this publication was to provide an overview 
of criteria that can be used for decision-making, rather 
than to provide an overview of which criteria are (widely) 
used in different decision making settings, as was the 
purpose in other publications [5, 6, 35]. Second, the 
quantification of how often or rarely a criterion is used 
does not necessarily imply its relevance for a given deci-
sion-making process: we believe that relevance should be 
informed by normative considerations. Third, there is a 
pronounced heterogeneity in the included studies: this 
begs the question, whether a criterion used in decision-
making in a local hospital should count as much as the 
criteria used in the health technology assessment process 
of a national or supra-national organization. Finally, the 
quantification of the use of criteria is complicated: not 
only were many studies cited in several included reviews 
[61], but some of the reviews referred to other reviews as 
their data sources [6, 38].
Strengths and limitations
Our focus of the literature search on a single data base 
(PubMed) and the reliance on a selection of terms such 
as “criteria/criterion” might have missed relevant studies 
conducted on this issue. These decisions were made due 
to significant time and resource constraints relating to 
the development of the WHO-INTEGRATE framework 
over a relatively short period of time. We countered this 
potential limitation by thoroughly searching the refer-
ences of all included studies, which yielded some addi-
tional publications. Furthermore, during the extraction 
of the criteria from included reviews we noted that we 
seemed to have reached saturation, as from the mid-way 
point, additional extracted studies yielded no or minimal 
additional criteria. Expanding the search to additional 
databases, especially those in the fields of political sci-
ences and health economics, with a more inclusive search 
strategy may yield valuable additional insights from a 
broader range of disciplines.
A significant strength of our publication is that—to the 
best of our knowledge—it is the most extensive overview 
of criteria used in or proposed for health decision mak-
ing. We included studies from several different health 
fields, conducted on various levels of decision-making 
and topics and in heterogeneous contexts around the 
world. We classified this comprehensive and diverse 
set of criteria according to a theory-based categoriza-
tion system comprising three levels, i.e. criteria, sub-
criteria and decision aspects. In doing so, as a team we 
critically reflected on extracted criteria and their under-
lying rationale, seeking to be as consistent as possible in 
how we sorted criteria reported in included reviews into 
higher-order categories.
Implications for policy and practice
The very large number of criteria and sub-criteria identi-
fied in this publication highlights the complexity of health 
decision-making It can serve as a resource when consid-
ering which criteria to include in sound multi-criteria 
approaches (i.e. adhering to principles of completeness, 
lack of redundancy, mutual independence, operationaliz-
ability and clustering) and how to use these.
The challenge of selecting the right criteria
At the centre of any decision-making process will be the 
challenge of who selects which criteria and how they 
should be weighted or ranked against each other. As vari-
ous stakeholders with diverging but reasonable motives 
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are likely to disagree on which criteria are the right ones, 
the focus often shifts from selecting the right criteria to 
making decisions using a good or fair process [16, 62]. 
Numerous procedural conditions which character-
ize such a fair process have been proposed, including in 
the Accountability for Reasonableness framework [16], 
among others [63–66]. A fair and transparent process 
and especially an adequate representation and partici-
pation of all relevant stakeholder groups is essential for 
achieving legitimacy [62, 63].
One approach to overcoming reasonable disagree-
ment about criteria for decision making is to reflect on 
the underlying normative principles and to make them 
explicit, e.g. by exploring the roots of a conflict which 
may lie in (potentially) conflicting normative arguments, 
e.g. if improving the life of a large number of people has 
to be weighed against the interest of those suffering from 
rare diseases with no alternative treatment. While we 
extracted such principles in our overview of reviews, oth-
ers have focused explicitly on these [18, 58, 60] and sev-
eral frameworks to guide the discussions and selection 
process have been proposed in the public health ethics 
literature [59, 60, 64, 65, 67–74].
Furthermore, underlying motives and drivers of stake-
holders should be taken into account when reflecting on 
proposed criteria, as these can manifest themselves as tro-
jan horses cloaked in ethical rhetoric [75]. Some calls for 
strengthening the consideration of criteria beyond evidence 
of effectiveness or incremental cost-effectiveness ratios are 
motivated by vested interest in a specific outcome [27, 76]. 
Such conflicts of interest should not necessarily lead to dis-
miss the arguments made, but it should lead to a critical 
reflection regarding the relevance and appropriateness of 
the proposed criteria for a given decision-making process 
and the power relations in the discourse [75, 77].
The challenge of resolving conflicts within and between 
criteria
The criteria by themselves are often highly intercon-
nected and at times conflicting. An example is the crite-
rion “age”, which can serve as a “surrogate” criterion for 
other normative and (harder to measure) considerations. 
For example, a focus on interventions targeting younger 
people may be motivated by their potential for achiev-
ing a longer life span (greater health impact) or to reduce 
productivity losses (positive impact on the economy). 
At the same time, “age” can be considered with respect 
to non-discrimination or equity: explicitly reflecting on 
age in order not to prioritize one group of people based 
on age as a characteristic (ageism). An explicit reflec-
tion on and discussion of such conflicts within criteria is 
important.
Furthermore, the criteria identified in the included 
reviews are partly overlapping (e.g. cost, effective-
ness, and cost-effectiveness). Depending on the deci-
sion-making process and the tools used (e.g. MCDA), 
accounting for overlaps and redundancies may be of 
relevance. This can, for example, be achieved through 
selecting non-overlapping criteria or through increas-
ing the granularity of the criteria. In particular the 
MCDA-literature has developed methods and guidance 
on how to identify and handle overlapping criteria [78].
The example of “age” as a criterion that can have 
conflicting interpretations highlights the need to set 
up a mechanism for handling conflicts within criteria 
and balancing interests in place. The same holds true 
for conflicts between criteria (e.g. positive impact on 
population health, negative impact on the natural envi-
ronment), which occur on a regular basis in decision-
making processes.
The challenge of using criteria
Populating criteria with evidence presents a third 
important challenge [15]. Evidence collection and syn-
thesis approaches are well developed for some criteria 
(e.g. health impacts) although some challenges remain. 
For a few criteria, approaches are virtually non-existent 
in the literature on health decision-making (e.g. envi-
ronmental implications) while for others there is a lack 
of clarity regarding the best methods to be employed 
(e.g. societal or environmental impact assessments) 
[15]. It is highly likely that suitable methods exist out-
side of the health decision-making or broader health-
care and public health literature and learning from 
other disciplines may offer solutions to this challenge.
Guideline development, HTA and other decision-
making processes aiming to integrate evidence and 
criteria for decision making in a structured manner 
usually operate under significant time and resource 
constraints. To avoid treating criteria beyond effec-
tiveness and cost-effectiveness as an “after thought”, 
evidence will need to be collected or analysis on these 
other criteria. This will require the development of 
rapid and pragmatic approaches to keep such decision-
making processes feasible.
Conclusion
The comprehensive list of criteria from and for real-world 
health decision-making presented here was an essential 
building block in the development of the WHO-INTE-
GRATE framework. We postulate that it can also be a 
useful stand-alone tool to inform health decision-making 
processes not employing an EtD framework. To make the 
best possible use of this list, solutions to the challenges of 
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selecting criteria, of resolving conflicts between criteria 
or their interpretation, and of identifying and appraising 
evidence towards these criteria will need to be found. The 
WHO-INTEGRATE framework seeks to address some 
of these challenges, by providing a set of criteria selected 
based on a strong normative basis and by offering a 
methodological toolbox, which suggests both compre-
hensive and pragmatic approaches to populating criteria 
with evidence [15].
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